• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

研究与包括儿科患者在内的临床试验完成情况相关的因素:对欧洲临床试验数据库的回顾性分析和来自欧洲区域的经验教训。

Study factors associated with the incompletion of clinical trials that include pediatric patients: a retrospective analysis of the European Clinical Trials Database and a lesson from the European region.

机构信息

National Institute of Health and Nutrition, National Institutes of Biomedical Innovation, Health and Nutrition, Tokyo, Japan.

Chiba University Hospital, Chiba, Japan.

出版信息

Trials. 2021 Mar 12;22(1):204. doi: 10.1186/s13063-021-05143-6.

DOI:10.1186/s13063-021-05143-6
PMID:33706800
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7953620/
Abstract

BACKGROUND

Incomplete clinical trials for pediatric drug development result in a lack of adequate scientific evidence for providing appropriate medication to pediatric populations; this is especially true for Japan. Thus, using the European Clinical Trials Database (EudraCT), this study aimed to identify the factors related to the study design and administration that lead to incompletion of clinical trials that included pediatric patients.

METHODS

We focused on clinical trials that included patients under the age of 18 registered in the database, named as the European Clinical Trials Database between January 1, 2014, and December 31, 2018. Two groups of trials were identified: "all cases completed" and "not all cases completed," reflecting whether they were completed in all participating countries/regions or not. To identify the factors of the occurrence of "not all cases completed," a logistic regression analysis was performed to calculate the odds ratios and 95% confidence intervals. In total, 142 clinical trials (95 "all cases completed" and 47 "not all cases completed") were analyzed.

RESULTS

The logistic regression analysis showed the number of countries in which a clinical trial was conducted to be the only significant factor (odds ratio: 1.3; 95% confidence interval: 1.1-1.5); this was identified as the primary factor for the occurrence of "not all cases completed" in the clinical trials that included pediatric patients.

CONCLUSION

Our findings suggest that the feasibility of clinical trials that include pediatric patients, such as whether the countries in which the trial is to be conducted are suitable, must be considered prior to the trial.

摘要

背景

儿科药物开发的临床试验不完整导致缺乏为儿科人群提供适当药物的充分科学证据;日本尤其如此。因此,本研究利用欧洲临床试验数据库(EudraCT),旨在确定与研究设计和管理相关的因素,这些因素导致包含儿科患者的临床试验无法完成。

方法

我们专注于在数据库中注册的年龄在 18 岁以下的患者的临床试验,这些临床试验被命名为 2014 年 1 月 1 日至 2018 年 12 月 31 日期间的欧洲临床试验数据库。确定了两组试验:“所有病例均完成”和“并非所有病例均完成”,反映了它们是否在所有参与国家/地区完成。为了确定“并非所有病例均完成”发生的因素,进行了逻辑回归分析,以计算优势比和 95%置信区间。总共分析了 142 项临床试验(95 项“所有病例均完成”和 47 项“并非所有病例均完成”)。

结果

逻辑回归分析表明,临床试验进行的国家数量是唯一的重要因素(优势比:1.3;95%置信区间:1.1-1.5);这被认为是包含儿科患者的临床试验中发生“并非所有病例均完成”的主要因素。

结论

我们的研究结果表明,在进行临床试验之前,必须考虑包含儿科患者的临床试验的可行性,例如将要进行试验的国家是否合适。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b567/7953620/40eeaf65ff40/13063_2021_5143_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b567/7953620/40eeaf65ff40/13063_2021_5143_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b567/7953620/40eeaf65ff40/13063_2021_5143_Fig1_HTML.jpg

相似文献

1
Study factors associated with the incompletion of clinical trials that include pediatric patients: a retrospective analysis of the European Clinical Trials Database and a lesson from the European region.研究与包括儿科患者在内的临床试验完成情况相关的因素:对欧洲临床试验数据库的回顾性分析和来自欧洲区域的经验教训。
Trials. 2021 Mar 12;22(1):204. doi: 10.1186/s13063-021-05143-6.
2
Noncompletion and nonpublication of trials studying rare diseases: A cross-sectional analysis.罕见病研究试验的完成和发表情况:一项横断面分析。
PLoS Med. 2019 Nov 21;16(11):e1002966. doi: 10.1371/journal.pmed.1002966. eCollection 2019 Nov.
3
Improvement of Pediatric Drug Development: Regulatory and Practical Frameworks.儿科药物研发的改进:监管与实践框架
Clin Ther. 2016 Mar;38(3):574-81. doi: 10.1016/j.clinthera.2016.01.012. Epub 2016 Feb 8.
4
[Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].[儿科药物研发:美国、欧盟和日本境内的国际人用药品注册技术协调会三方协调指导原则E11]
Arch Pediatr. 2014 Oct;21(10):1129-38. doi: 10.1016/j.arcped.2014.07.011. Epub 2014 Aug 28.
5
Updated analysis of pediatric clinical studies registered in ClinicalTrials.gov, 2008-2019.2008-2019 年在 ClinicalTrials.gov 上注册的儿科临床研究的更新分析。
BMC Pediatr. 2021 Apr 30;21(1):212. doi: 10.1186/s12887-021-02658-4.
6
Factors associated with radiation therapy incompletion for patients with early-stage breast cancer.早期乳腺癌患者放疗未完成的相关因素。
Breast Cancer Res Treat. 2016 Jan;155(1):187-99. doi: 10.1007/s10549-015-3660-4. Epub 2015 Dec 18.
7
Delays in completion and results reporting of clinical trials under the Paediatric Regulation in the European Union: A cohort study.欧盟《儿童用药规例》下临床试验完成和结果报告的延误:一项队列研究。
PLoS Med. 2018 Mar 1;15(3):e1002520. doi: 10.1371/journal.pmed.1002520. eCollection 2018 Mar.
8
Prevalence and outcomes of pediatric in-hospital cardiopulmonary resuscitation in the United States: an analysis of the Kids' Inpatient Database*.美国儿科院内心肺复苏的发生率和结局:对儿童住院数据库的分析*。
Crit Care Med. 2012 Nov;40(11):2940-4. doi: 10.1097/CCM.0b013e31825feb3f.
9
Randomized controlled trials in pediatric patients had higher completion rates than adult trials: a cross-sectional study.儿科患者的随机对照试验完成率高于成人试验:一项横断面研究。
J Clin Epidemiol. 2018 Aug;100:53-60. doi: 10.1016/j.jclinepi.2018.04.018. Epub 2018 Apr 26.
10
Industry Perspective of Pediatric Drug Development in the United States: Involvement of the European Union Countries.美国儿科药物研发的行业视角:欧盟国家的参与情况
Ther Innov Regul Sci. 2018 Jan;52(1):49-56. doi: 10.1177/2168479017716718. Epub 2017 Jun 30.

引用本文的文献

1
Development and performance of the c4c national clinical trial networks for optimizing pediatric trial facilitation.用于优化儿科试验促进的c4c国家临床试验网络的开发与性能
Front Pediatr. 2023 Dec 21;11:1302272. doi: 10.3389/fped.2023.1302272. eCollection 2023.

本文引用的文献

1
The patient's view on rare disease trial design - a qualitative study.患者对罕见病临床试验设计的看法——一项定性研究。
Orphanet J Rare Dis. 2019 Feb 7;14(1):31. doi: 10.1186/s13023-019-1002-z.
2
Innovative Study Designs Optimizing Clinical Pharmacology Research in Infants and Children.创新研究设计优化婴儿和儿童临床药理学研究。
J Clin Pharmacol. 2018 Oct;58 Suppl 10(Suppl 10):S58-S72. doi: 10.1002/jcph.1053.
3
Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: A review.
与失败的临床试验相关的因素及提高成功可能性的机会:一项综述。
Contemp Clin Trials Commun. 2018 Aug 7;11:156-164. doi: 10.1016/j.conctc.2018.08.001. eCollection 2018 Sep.
4
Roles of Clinical Research Networks in Pediatric Drug Development.临床研究网络在儿科药物研发中的作用。
Clin Ther. 2017 Oct;39(10):1939-1948. doi: 10.1016/j.clinthera.2017.09.001. Epub 2017 Sep 22.
5
Challenges of developing and conducting clinical trials in rare disorders.在罕见病中开展和进行临床试验的挑战。
Am J Med Genet A. 2018 Apr;176(4):773-783. doi: 10.1002/ajmg.a.38413. Epub 2017 Aug 16.
6
Clinical Trial Application in Europe: What Will Change with the New Regulation?欧洲的临床试验申请:新法规会带来哪些变化?
Sci Eng Ethics. 2016 Apr;22(2):451-66. doi: 10.1007/s11948-015-9662-0. Epub 2015 Jun 3.
7
Balancing the interests of patient data protection and medication safety monitoring in a public-private partnership.平衡公私合作中患者数据保护和药物安全监测的利益。
JMIR Med Inform. 2015 Apr 15;3(2):e18. doi: 10.2196/medinform.3937.
8
Prevalence, characteristics, and publication of discontinued randomized trials.停止的随机试验的流行率、特征和发表情况。
JAMA. 2014 Mar 12;311(10):1045-51. doi: 10.1001/jama.2014.1361.
9
Paediatric drug development: the impact of evolving regulations.儿科药物研发:监管演变的影响。
Adv Drug Deliv Rev. 2014 Jun;73:2-13. doi: 10.1016/j.addr.2014.02.003. Epub 2014 Feb 18.
10
Clinical trials in children.儿童临床试验。
Br J Clin Pharmacol. 2015 Mar;79(3):357-69. doi: 10.1111/bcp.12305.